Related references
Note: Only part of the references are listed.A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review
Limor Amit et al.
PLOS ONE (2013)
Dehiscence of Corticosteroid-Induced Abdominal Striae in a 14-Year-Old Boy Treated With Bevacizumab for Recurrent Glioblastoma
Helen Wheeler et al.
JOURNAL OF CHILD NEUROLOGY (2012)
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer Safety of Avastin in Lung trial (MO19390)
Janessa Laskin et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 20052009
Therese A. Dolecek et al.
NEURO-ONCOLOGY (2012)
First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study
Christoph Thomssen et al.
ONCOLOGY (2012)
Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
Cornelia Schuster et al.
PLOS ONE (2012)
AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
O. L. Chinot et al.
ADVANCES IN THERAPY (2011)
Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy
Katherine B. Peters et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy
Tyler J. Fraum et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma
Teri N. Kreisl et al.
NEURO-ONCOLOGY (2011)
Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study
Sridharan Gururangan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and Handling Strategies
Fabio Girardi et al.
ONCOLOGIST (2010)
Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?
Christos Vaklavas et al.
ONCOLOGIST (2010)
Intricacies of Bevacizumab-induced Toxicities and Their Management
Sarah M. Gressett et al.
ANNALS OF PHARMACOTHERAPY (2009)
Thrombosis associated with angiogenesis inhibitors
Francesca Elice et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2009)
Toxicity of Targeted Therapy in Non-Small-Cell Lung Cancer Management
Serena Ricciardi et al.
CLINICAL LUNG CANCER (2009)
Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma
Dale R. Shepard et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
BEVACIZUMAB AS THERAPY FOR RADIATION NECROSIS IN FOUR CHILDREN WITH PONTINE GLIOMAS
Arthur K. Liu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Adverse effects of anticancer agents that target the VEGF pathway
Helen X. Chen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients
Uwe Pichlmeier et al.
NEURO-ONCOLOGY (2008)
Malignant gliomas in adults
Patrick Y. Wen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Thomas E. Hutson et al.
ONCOLOGIST (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma
MN Tsao et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
FF Kabbinavar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review
N Laperriere et al.
RADIOTHERAPY AND ONCOLOGY (2002)
Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft
DF Stefanik et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Share Paper
